Abstract 1985P
Background
Sarcomas are rare mesenchymal tumors that require multidisciplinary care. Referral centres receiving patients (pts) from peripheral set-ups face challenges which highlight the need for expert sarcoma pathology and specialised treatment.
Methods
This is a retrospective study in pts referred with pathological and/or clinico-radiological diagnosis of sarcoma (January 2021 to December 2022). Clinical, diagnostic, prior treatment details were reviewed from records. Pathologic discordances (PD) were classified as major (sarcoma to carcinoma or benign, soft tissue sarcoma to bone sarcoma or vice versa, any change influencing treatment) or minor.
Results
539 pts included (incl) 58% males (n=312) with median age of 35 (1-89 years), residing at median distance of 160 kilometres (km) (3-2600) from our centre. Median presenting time was 11 months (15 days-20 years) from symptom onset; recurrent/metastatic (n=255, 47%) and locally advanced (n=134, 25%) stages predominated. Common primary sites were extremity (45.5%), abdomen (27%) with symptoms of pain (67%) and swelling (64%). 499 (92.5%) pts had pathology reports from outside and available comparison (n=372) showed 42.9% discordance (16.3% major, 26.6% minor) (Table). Sarcoma diagnosis changed to benign (1.3%), carcinoma (1.3%), fibromatosis (0.2%), germ cell tumor (0.2%) after review. Ultra-rare sarcomas (URS) (n=33, 6%) showed higher PD (73%). Molecular testing was done in 4.6% (n=11) of pts with testing indications. Most had received treatment outside (surgery in 50.6%, chemotherapy in 32.6%); deviation from standard guidelines was noted in 39.7% chemotherapy and 8.7% surgeries (Table). Univariate analysis did not yield significant factors associated with diagnostic or treatment discordance. Table: 1985P
Details of subjects and discordances in diagnosis and treatment
Diagnosis | Treatment |
Subtypes Soft tissue sarcoma (STS) = 295 (54.7%) Bone sarcoma (BS) = 100 (18.5%) Carcinoma = 7 (1.2%) Benign = 7 (1.2%) Others = 10 (2%) Undifferentiated = 1 (0.2%) Discordances a) Major = 61 (16.3%) b) Minor = 99 (26.6%) Major discordance: a) Change of sarcoma subtype = 39 (64%) b) Benign to malignant = 14 (11.7%) c) Carcinoma to sarcoma = 4 (6.5%) d) Low to high grade = 4 (6.5%) e) BS to STS = 3 (5%) | Chemotherapy a) Incorrect regimen (n=28, 16%) b) Inadequate dose/cycles (n=20, 11.3%) c) Not given despite indication (n=17, 9.6%) d) Others (n=4, 2.2%) Surgery a) Inadequate surgery (n=19, 7%) b) Surgery without staging (n=5, 2%) |
Conclusions
The significant discrepancies noted in diagnosis and management of pts in this study highlight the importance of expert pathologists and early referral for better treatment outcomes in sarcomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15